Effect of obesity on patients with advanced non-small cell lung cancer

July 25, 2013

Obesity increases health risks for many things. Researchers wanted to know the impact of obesity on outcomes of patients with advanced non-small cell lung cancer. In the September issue of the International Association for the Study of Lung Cancer's journal, the Journal of Thoracic Oncology (JTO), researchers conclude that obese patients had superior outcomes early on in the study, but then experienced increased hazards.

During the period from 1993 to 2004, the Eastern Cooperative Oncology Group enrolled 2684 patients to three phase III trials of first-line systemic chemotherapy for advanced NSCLC. At a median follow-up of 64.9 months, 2585 of the patients were declared eligible and included in this research. The patients had their (BMI) calculated. Consistent with the general population, 4.6 percent of patients were underweight, 44.1 percent were normal weight, 34.3 percent of patients were classified as overweight, and 16.9 percent were obese.

The median overall survival estimated among underweight patients was 7.0 months, among normal weight patients was 8.6 months, among overweight patients was 9.3 months and among was 11.0 months.

In multivariable models, obese patients had significantly different overall survival when compared with normal-weight and overweight patients; however, their risk of death from any cause increased dramatically once they had been on study longer than 16 months.

Researchers says, "this indicates that the protective effect of obesity in is for a limited time, after which the ultimate impact of obesity on survival from all causes supersedes."

Explore further: Obese kidney failure patients receive survival benefit from transplantation

Related Stories

Obese kidney failure patients receive survival benefit from transplantation

July 25, 2013
Most obese individuals with kidney failure can prolong their lives by receiving a kidney transplant, although this survival benefit is lower in severely obese individuals. That's the conclusion of a new study published in ...

Obesity, overweight at diagnosis ups B-cell lymphoma prognosis

May 30, 2012
(HealthDay) -- For U.S. veterans with diffuse large B-cell lymphoma (DLBCL), being overweight or obese at time of diagnosis correlates with improved survival, according to a study published online May 29 in the Journal of ...

Latest research shows two items are key to decrease symptoms and prolong survival for LMC patients

April 22, 2013
Lung cancer is one of the most common primary cancers that cause leptomeningeal carcinomatosis (LMC), when cancer spreads to the membranes surrounding the spinal cord and brain. Cases of LMC have increased because of the ...

Fitness, obesity independently affect cardiometabolic risk

April 3, 2013
(HealthDay)—Fitness and obesity are independently associated with cardiometabolic (CM) risk, according to a study published in the April 1 issue of The American Journal of Cardiology.

Obesity linked to worse outcomes in early breast cancer treatment

December 8, 2011
Obesity is associated with worse outcomes overall in early-stage breast cancer, researchers reported at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011.

Obese patients trust diet advice from overweight physicians more than normal-weight physicians

June 4, 2013
When it comes to taking diet advice from a physician—size matters. This is according to a new study led by a team of researchers at the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins University School ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

gaucho25
not rated yet Jul 26, 2013
A new FDA approved diet pill called Belviq just went on the market. Belviq make people more likely to succeed with weight loss since they feel full more quickly and it reduces food cravings. People who take Belviq with diet and exercise were 2 times more likely to lose 5% body weight and 3 times more likely to lose 10% body weight than the people who just did diet and exercise alone. The label states that if you do not lose 5% of your body weight in 12 weeks then consider stopping. Those that do respond in 12 (about 45% of patients) weeks go on to lose over 10% of their body weight in one year. Losing 22 pounds for a 220 pound person is life changing. So for 45% of those taking Belviq lose significant amount of weight.
Belviq has a second mode of action to reduce blood sugar which may end up preventing diabetes in many cases. Diabetics and pre-diabetics who took Belviq, regardless of weight loss, saw their blood sugar numbers drop by double digit percentages. IE HbA1c -0.9 / -1.2

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.